卡铂联合化疗治疗老年非小细胞肺癌剂量探讨

A Study on Dose Level of Carboplatin Combined Chemotherapy in Treatment of Elder Non small Cell Lung Cancer

摘要: 目的探讨老年非小细胞肺癌患者联合化疗时卡铂按AUC=5mg/ml·min(AUC,areaundertheconcentrationtimecurve)的剂量是否适宜。方法33例老年晚期非小细胞肺癌患者采用Taxol+CBP、Gemzar+CBP、NVB+CBP方案化疗,卡铂用药剂量按AUC=5的水平给药。全部患者共完成73周期化疗。每周期化疗前后对患者的化疗毒副反应及生活质量变化进行评估。结果骨髓毒副反应常见且较重,中性粒细胞出现Ⅲ/Ⅳ级副反应为47.9%(35/73)、血小板出现Ⅲ/Ⅳ级副反应为28.8%(21/73)。其余毒副反应不重。生存质量评分(依据国内肿瘤患者生存质量评分标准)平均下降6.5分。结论老年非小细胞肺癌患者联合化疗时,卡铂按AUC=5的剂量水平用药毒副反应较重,且对生存质量有不利影响,可能与剂量偏大有关。

Abstract: Objective Preliminarily to determine whether it was appropriate for elder patients with non small cell lung cancer to be treated by carboplatin at AUC=5 mg/ml·min level during combined chemotherapy. Methods 33 cases of elder patients with non small cell lung cancer in advanced stage had received 73 cycles combination chemotherapy. Chemotherapy schemes included Taxol+CBP,Gemzar+CBP and NVB+CBP. The dose of carboplatin was at AUC=5 mg/ml·min level (AUC, area under the concentration time curve). Side effects an...